fn1

NCGC00378430 是一种 SIX1 EYA2 相互作用抑制剂。它部分逆转 SIX1 过表达介导的转录和代谢谱，并逆转 SIX1 诱导的 TGF-β 信号传导和上皮-间质转化。在小鼠模型中，它能够抑制 SIX1 介导的乳腺癌转移。

Pfn1-IN-C1, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

Pfn1-IN-C2, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) 是一种 TWEAK-Fn14 信号级联抑制剂。

FN-1501-propionic acid, a CDK2 9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2 9 degrader.

FN-1501 是一种有效的 FLT3 和 CDK 抑制剂，具有抗肿瘤的活性，对 CDK2 cyclin A、CDK4 cyclin D1、CDK6 cyclin D1 和 FLT3 的 IC50值分别为 2.47、0.85、1.96 和 0.28 nM。

FFN-102 (trifluoroacetate salt) 是一种合成的生物源性神经递质类似物，具有 PH 依赖性荧光和电活性。

StA-IFN-1 is an inhibitor of the interferon (IFN) induction pathway with an IC50 value of 4.1 μM in a GFP reporter assay for IFN induction similar to TPCA-1 , which specifically inhibits the IKKβ component of the IFN induction pathway. It does not show inhibitory activity in a GFP reporter assay for IFN signaling in which ruxolitinib , which is specific for the IFN signaling component JAK1, is active. StA-IFN-1 reduces the levels of IFN-β, but not ISG MxA, mRNA, suggesting that it is selective for the IFN induction pathway and not the IFN signaling pathway.

AFN-1252 (Debio 1452)是一种FabI 的高效抑制剂，能抑制金黄色葡萄球菌。

AFN-1252 tosylate is an enoyl-ACP Reductase inhibitor.

SC 53606 is a potent and selective antagonist of 5-hydroxytryptamine4 receptor.

AMPCP is an Ecto-5'-nucleotidase (CD73) inhibitor.

AFN-1252, also known as AFN-12520000; API-1252; Debio-1452, is FASII Inhibitor which is potentially for the treatment of acute bacterial skin. AFN-1252 exhibits typical MIC(90) values of ≤0·015 μg ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. AFN-1252 efficiently blocked daptomycin-induced phospholipid decoy production, even in the case of isolates resistant to AFN-1252, which prevented the inactivation of daptomycin and resulted in sustained bacterial killing. In turn, daptomycin prevented the fatty acid-dependent emergence of AFN-1252-resistant isolates in vitr

BAY 2666605 是一种具有口服活性的 PDE3A 和 PDE3B 抑制剂，IC50 分别为 87 nM 和 50 nM。 BAY 2666605 具有抗癌作用。

GED-0507-34 Levo((S)-3-(4-氨基苯基)-2-甲氧基丙酸)是一种可口服的PPARγ调节剂，用于改善炎症驱动的肠道纤维化，降低了促纤维化基因Acta2、COL1a1和Fn1的表达，减少了纤维化主要标志物α-SMA和胶原蛋白I-II的蛋白水平，以及TGFβ Smad途径的主要成分，降低了IL-13、CTGF、TGFB和ACTA1的表达，抑制了TGF-β诱导的成纤维细胞和IECs细胞系的活化。